Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

85.40 +1.20 (+1.43%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What 9 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

November 15, 2021

Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ:

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Analyst Ratings For Protagonist Therapeutics ↗

October 12, 2021

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:

Via Benzinga

Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month ↗

November 08, 2021

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Via The Motley Fool

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List ↗

November 01, 2021

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...

Via Benzinga

5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger ↗

October 25, 2021

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...

Via Benzinga

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

What 10 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 13, 2021

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

October 13, 2021

MKM Partners raised the price target on Continental Resources, Inc. (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 12, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 ↗

October 12, 2021

Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

October 12, 2021

Evercore ISI Group raised Lear Corporation (NYSE:

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 12, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...

Via Talk Markets

Topics Stocks

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 11, 2021

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

Where Protagonist Therapeutics Stands With Analysts ↗

October 11, 2021

Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ...

Via Benzinga

Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals ↗

October 11, 2021

Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...

Via Benzinga

Topics Stocks

28 Stocks Moving In Monday's Mid-Day Session ↗

October 11, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...

Via Benzinga

PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today ↗

October 11, 2021

Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.

Via InvestorPlace

Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug ↗

October 11, 2021

Protagonist Therapeutics can now restart dosing patients in its rusfertide studies.

Via Investor's Business Daily

Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program ↗

October 11, 2021

The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 11, 2021

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy ↗

October 05, 2021

When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock.

Via InvestorPlace

PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

September 22, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

58 Biggest Movers From Yesterday ↗

September 24, 2021

Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362...

Via Benzinga

20 Stocks Moving in Wednesday's Pre-Market Session ↗

September 22, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 21, 2021

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

All News about Protagonist Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today